Research
Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital
Published

Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Drug-related challenges following primary total hip and knee arthroplasty

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Camostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety

    Research output: Contribution to journalReviewResearchpeer-review

  3. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Research output: Contribution to journalReviewResearchpeer-review

  4. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Number of Traumatic brain injuries and temporal associations with depression: A register-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Thromboembolic and bleeding complications following primary total knee arthroplasty: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Using machine learning for predicting intensive care unit resource use during the COVID-19 pandemic in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Duloxetine Exposure During Pregnancy and the Risk of Spontaneous and Elective Abortion: A Danish Nationwide Observational Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The aim of this study was to validate registration of pharmacological treatment in the Danish Hip Arthroplasty Register (DHR) and Danish Knee Arthroplasty Register (DKR). We conducted a population-based study in the Capital Region of Denmark, January 2012 to April 2016. Positive predictive value (PPV) and sensitivity were calculated with 95% confidence intervals (CI) for antithrombotic, antihemorrhagic and antibiotic treatment registered in the DHR and DKR using electronic health records as the reference standard. For the DHR, the PPV and sensitivity were 77.9% (95% CI: 77.2-78.6) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, 70.9% (95% CI: 70.1-71.7) and 97.4% (95% CI: 97.1-97.7) for antihemorrhagic treatment, and 82.9% (95% CI: 82.2-83.5) and 99.4% (95% CI: 99.3-99.5) for antibiotic treatment, respectively. For the DKR, the PPV and sensitivity were 80.6% (95% CI: 79.8-81.4) and 99.6% (95% CI: 99.4-99.7) for antithrombotic treatment, and 84.4% (95% CI: 83.7-85.1) and 100.0% (95% CI: 99.9-100.0) for antibiotic treatment, respectively. The PPV and sensitivity for overall pharmacological treatment registered in the DHR and DKR were generally high and acceptable for use in research.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
Volume128
Issue number3
Pages (from-to)455-462
Number of pages8
ISSN1742-7843
DOIs
Publication statusPublished - Mar 2021

Bibliographical note

© 2020 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

    Research areas

  • clinical registers, drug use, electronic health record data, pharmacoepidemiology, validation study

ID: 61103974